I'm not convinced they are on track. If you go back to the original PR's for ESSI, you will see that over a year ago they had a team of professionals and promised updates on where they were in regards to trials and so on back then. Now - where are all the Doctors? Where has all that news been? The updates? This stock is just a promise for the future - and with no money, if their aim is to be able to fund this venture, sooner or later you are most likely looking at dilution and PR.
BEVERLY HILLS, Calif., Sept. 25, 2012 /PRNewswire/ --Eaton Scientific Systems, Ltd. ("Eaton" or the "Company") a wholly-owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased provide this outline of the market potential of Tropine 3 for the non-hormonal treatment for pre-menopausal, peri-menopausal, and post-menopausal women experiencing hot flashes.
"Menopause and the effects of hot flashes in particular are without a doubt one of the most significantly important health issues facing many women today, and as a result, the opportunity to provide women with a safe and effective treatment to reduce or eliminate hot flash symptoms is enormous," stated Michael Borkowski, CEO of Eaton Scientific. "Traditional hormone treatments have been shown to cause a dramatic increase in the risk of breast cancer and cardiovascular disease. Improved awareness of these health risks has led to a high unmet demand for non-hormonal treatment options. As a result, novel non-hormonal treatments such as Tropine 3 are poised to overtake traditional hot flash treatments."
In 2010, the women's health therapeutics market was calculated to be worth approximately $14.5 billion. GBI Research, a leading business intelligence provider, forecasts the market to grow at a Compound Annual Growth Rate (CAGR) of 7.9% between 2010 and 2017 to record a sales value of approximately $24.7 billion in 2017. Novel non-hormonal therapeutics such as Tropine 3 are expected to become increasingly popular during the forecast period. Based on current and expected market conditions, the Company estimates that Tropine 3, if successfully tested and promoted, has a global market potential in excess of $500 million in annual sales.
The Company is currently finalizing arrangements for conducting Phase 1 & 2 clinical trials of Tropine 3 with the goal of final FDA approval. Additional information regarding clinical trial start dates will be made available shortly
AI
